E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Monocarboxylate Transporter 8 (MCT8) deficiency |
|
E.1.1.1 | Medical condition in easily understood language |
MCT 8 deficiency or AHDS (Allan-Herndon-Dudley syndrome) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effects of withdrawal of tiratricol treatment (placebo group) on serum total triiodothyronine (T3) concentrations, measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS), and the requirement for rescue treatment with tiratricol as compared to continuing tiratricol treatment (tiratricol group), in males diagnosed with MCT8 deficiency and on a stable maintenance dose of tiratricol |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the safety and tolerability of tiratricol treatment 2. To evaluate the effect of tiratricol treatment upon serum thyroid hormone measurements, sex hormone binding globulin (SHBG), and cardiovascular measurements 3. To evaluate the serum concentrations of tiratricol
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male participants diagnosed with a pathogenic mutation in the MCT8 gene, confirmed with a genetic test. 2. Serum total T3 concentration above the ULN of the age specific normal range : a) at the time of diagnosis (or the closest sample taken prior to first ever treatment with tiratricol) for participants who are currently treated with tiratricol (if serum total T3 concentration is not available, free T3 results from standard of care samples may be used). b) In the Screening Visit sample: i. For participants who have never received and/or are currently not receiving tiratricol. ii. For participants who stopped prohibited medications per exclusion criterion #6 3. Participants will be aged 4 years or older at the time of randomization. Participants entering screening who are <4 years of age but expected to be aged 4 years at randomization should be discussed with the medical monitor. 4. Signed and dated informed consent form from the parents or legal guardian.
|
|
E.4 | Principal exclusion criteria |
1. Major illness or recent major surgery unrelated to MCT8 deficiency (in the principal investigator’s judgement), defined as: • Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the trial. • Major illness in the 3 months prior to the Screening Visit that is likely to confound the ability of the participant to participate fully within the trial and/or confound the assessment of serum total T3 and/or safety. • Major surgery within the 3 months prior to the Screening Visit or planned to take place during the study, including but not limited to major abdominal/thoracic/neurosurgical procedures. • Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of study drug. 2. Body weight <10 kg at the Screening Visit. 3. Patients who are participating, or intend to participate, in other therapeutic and/or interventional clinical studies during the study period. 4. History of allergic reactions to components of tiratricol or any excipients in the investigational product (IP). 5. Participants with any contra-indication for treatment with tiratricol or any excipients in the IP. 6. Participants who have used other T3 analogues, levothyroxine, propylthiouracil, or other antithyroid medications within 6 weeks of screening
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of participants who meet the rescue criterion (serum total T3 > ULN) from samples obtained during the 30 day double-blind Randomized Treatment Period |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
end of Randomized Treatment period |
|
E.5.2 | Secondary end point(s) |
• Change in serum thyroid hormone variables (T3, T4, TSH, fT3, and fT4) from baseline (start of the Randomized Treatment Period) to the end of Randomized Treatment Period (completion or rescue) • Change in serum thyroid hormone variables (T3, T4, TSH, fT3, and fT4) from initiation of tiratricol administration at screening to the last measurement prior to randomization (Cohort B only) • Change in the cardiovascular variables from extended ECG assessments, 24 hour ABPM, and heart rate assessments from the last measurement prior to the start of the Randomized Treatment Period to the end of the Randomized Treatment Period (completion or rescue) • Serum concentrations of tiratricol • Change in serum SHBG from baseline (start of the Randomized Treatment Period) to the end of the Randomized Treatment Period (completion or rescue) • Time (days) from randomization to the time when the rescue criterion is met or the time of completion of the Randomized Treatment Period (whichever comes first)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
end of Randomized Treatment period
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United Kingdom |
United States |
Netherlands |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the date of the last investigational visit for the last patient undergoing protocol treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 12 |